InvestorsHub Logo
Post# of 252499
Next 10
Followers 832
Posts 119983
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 226231

Wednesday, 09/25/2019 5:37:10 PM

Wednesday, September 25, 2019 5:37:10 PM

Post# of 252499
ENTA—After listening to the CC and further contemplating the EDP-305 dataset reported today, I think ENTA should strongly consider switching from EDP-305 to the company's backup FXR compound.

EDP-305's pruritis rate at 2.5mg is too high, and it's unclear whether there's a bona fide therapeutic window for this drug.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.